囊链蛋白α和罕见和常见的神经退行性痴呆症之间的联系
Matthew J Rosene1, Bruno A Benitez1
1Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA USA.
概括
囊链蛋白α (CSPα) 功能障碍通过损害蛋白质质量控制,导致痴呆. 向CSPα为神经退行性疾病提供了一个新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 蛋白质稳态和质量控制对于神经元功能至关重要,在痴呆症中经常受到损害.
- 半氨酸串蛋白α (CSPα) 是一种参与囊泡融合和蛋白质稳定的内分泌体共蛋白.
- CSPα功能障碍与突触病和神经退行性疾病有关.
研究的目的:
- 提出一种新的CSPα相关痴呆症的分子和病理生理模型.
- 要突出CSPα在神经退行症中不断扩大的作用.
- 探索CSPα在疾病相关蛋白质分泌中的功能及其作为治疗点的潜力.
主要方法:
- 文献综述和现有CSPα研究的综合.
- 对CSPα在突触和内分泌体通路中的作用的分析.
- 探索CSPα在蛋白质分泌和神经退行过程中的参与.
主要成果:
- CSPα在突触维护和内分泌体功能中起着至关重要的作用.
- 在CSPα中发生的突变与成人发作的神经神经状脂症 (ANCL) 有关.
- CSPα通过MAPS和非常规途径参与聚合性蛋白质的分泌.
结论:
- CSPα是神经退行相关的突触和内分泌体通路的关键参与者.
- CSPα的作用扩展到常见神经退行性疾病中涉及的蛋白质的分泌.
- 调节CSPα为痴呆症和其他神经退行性疾病提供了一个有希望的治疗途径.
相关概念视频
Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K
The Proteasome
1.2K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.2K
Alzheimer's Disease: Overview
675
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
675
Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Cystic Fibrosis: Pathogenesis
369
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
369


